Tasisulam-induced suicidal death of human erythrocytes
Abdulla Al Mamun Bhuyan, Md Ashraf Zaman Faruk, Md Niamot Ali, Md Abu Choudhury, Mengzhou Xue, Chunfu Zheng, Florian Lang · 2026
Read Tasisulam-induced suicidal death of human erythrocytes by Abdulla Al Mamun Bhuyan, Md Ashraf Zaman Faruk, Md Niamot Ali, Md Abu Choudhury, Mengzhou Xue, Chunfu Zheng, Florian Lang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13426206.txt.
Description
Abdulla Al Mamun Bhuyan and colleagues tested whether the anticancer drug tasisulam kills red blood cells ahead of schedule in a 2026 laboratory study. Tasisulam promotes programmed death in tumor cells and is in trials for lung cancer, lymphoma, breast cancer, melanoma, and other tumors, yet anemia is a known adverse effect. The suspected route is eryptosis, premature red cell shrinkage with phosphatidylserine flipped to the surface.
Human red cells at low concentration were incubated with tasisulam doses of 75 and 150 units and checked for calcium rise, oxidative stress, ceramide build-up, and kinase or caspase activity. Defining that signaling helps explain drug-related anemia and suggests protective countermeasures.
Catalog record
| CREATOR | Abdulla Al Mamun Bhuyan, Md Ashraf Zaman Faruk, Md Niamot Ali, Md Abu Choudhury, Mengzhou Xue, Chunfu Zheng, Florian Lang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28304 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |